Summary
I am Senior Clinical Research Fellow in vaccinology and Honorary Consultant in genitourinary medicine at Imperial College London and Imperial College Healthcare NHS Trust. I read medicine at Newnham College, University of Cambridge, and Imperial College London before completing speciality training as a clinician scientist in genitourinary medicine and immunology. My research investigates diversity in T cell responses to accelerate discovery in vaccine design and implementation. I lead first-in-human trials and experimental medicine studies of novel vaccines against hard-to-target pathogens including HIV and chlamydia. I am Chief and Principal Investigator for the Imperial College London self amplifying RNA SARS-CoV-2 vaccine and Oxford Astra-Zeneca COVID-19 vaccine trials. I received a Department of Infectious Disease award for substantial and exceptional achievement during the COVID-19 pandemic.
Publications
Journals
Pollock KM, Cheeseman HM, Szubert AJ, et al.Pollock KM, Cheeseman HM, Szubert AJ, Libri V, Boffito M, Owen D, Bern H, O'Hara J, McFarlane LR, Lemm N-M, McKay PF, Rampling T, Yim YTN, Milinkovic A, Kingsley C, Cole T, Fagerbrink S, Aban M, Tanaka M, Mehdipour S, Robbins A, Budd W, Faust SN, Hassanin H, Cosgrove CA, Winston A, Fidler S, Dunn DT, McCormack S, Shattock RJ close, 2022, Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial, Eclinicalmedicine, Vol:44, ISSN:2589-5370, Pages:101262-101262
Cole ME, Guo Y, Cheeseman HM, et al.Cole ME, Guo Y, Cheeseman HM, Pollock KM close, 2022, Multicolor Flow Cytometry and High-Dimensional Data Analysis to Probe Complex Questions in Vaccinology., Methods Mol Biol, Vol:2414, Pages:433-447
Hodgson SH, Iveson P, Larwood J, et al.Hodgson SH, Iveson P, Larwood J, Roche S, Morrison H, Cosgrove C, Galiza E, Ikram S, Lemm N-M, Mehdipour S, Owens D, Pacurar M, Schumacher M, Shaw RH, Faust SN, Heath PT, Pollard AJ, Emary KRW, Pollock KM, Lazarus R close, 2021, Incidental findings in UK healthy volunteers screened for a COVID-19 vaccine trial, Cts-clinical and Translational Science, ISSN:1752-8054
Feng S, Phillips DJ, White T, et al.Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, Dold C, Fuskova M, Gilbert SC, Hirsch I, Humphries HE, Jepson B, Kelly EJ, Plested E, Shoemaker K, Thomas KM, Vekemans J, Villafana TL, Lambe T, Pollard AJ, Voysey M, Adlou S, Allen L, Angus B, Anslow R, Asselin M-C, Baker N, Baker P, Barlow T, Beveridge A, Bewley KR, Brown P, Brunt E, Buttigieg KR, Camara S, Charlton S, Chiplin E, Cicconi P, Clutterbuck EA, Collins AM, Coombes NS, Clemens SAC, Davison M, Demissie T, Dinesh T, Douglas AD, Duncan CJA, Emary KRW, Ewer KJ, Felle S, Ferreira DM, Finn A, Folegatti PM, Fothergill R, Fraser S, Garlant H, Gatcombe L, Godwin KJ, Goodman AL, Green CA, Hallis B, Hart TC, Heath PT, Hill H, Hill AVS, Jenkin D, Kasanyinga M, Kerridge S, Knight C, Leung S, Libri V, Lillie PJ, Marinou S, McGlashan J, McGregor AC, McInroy L, Minassian AM, Mujadidi YF, Penn EJ, Petropoulos CJ, Pollock KM, Proud PC, Provstgaard-Morys S, Rajapaska D, Ramasamy MN, Sanders K, Shaik I, Singh N, Smith A, Snape MD, Song R, Shrestha S, Sutherland RK, Thomson EC, Turner DPJ, Webb-Bridges A, Wrin T, Williams CJ close, 2021, Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection, Nature Medicine, Vol:27, ISSN:1078-8956, Pages:2032-2040
Flaxman A, Marchevsky NG, Jenkin D, et al.Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, Belij-Rammerstorfer S, Bibi S, Bittaye M, Cappuccini F, Cicconi P, Clutterbuck EA, Davies S, Dejnirattisai W, Dold C, Ewer KJ, Folegatti PM, Fowler J, Hill AVS, Kerridge S, Minassian AM, Mongkolsapaya J, Mujadidi YF, Plested E, Ramasamy MN, Robinson H, Sanders H, Sheehan E, Smith H, Snape MD, Song R, Woods D, Screaton G, Gilbert SC, Voysey M, Pollard AJ, Lambe T, and the Oxford COVID Vaccine Trial group close, 2021, Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002), The Lancet, Vol:398, ISSN:0140-6736, Pages:981-990
More Publications
